Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Nov 21, 2024•19 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast